Join Prof. Carle Paul as he presents his selection of Editor’s Picks from the September 2026 issue:
- Dose reduction of biologics in psoriasis: giving more freedom to patients
- Litifilimab for cutaneous lupus erythematosus
- Managing high impact-site psoriasis: an oral IL-23 Receptor inhibitor on the menu
- Comorbidities influence treatment response to immune checkpoint inhibitors in squamous-cell carcinoma
Read the Editor's Picks here: https://doi.org/10.1111/jdv.70607
